Regeneron Pharmaceuticals Inc (REGN)vsTheravance Biopharma Inc (TBPH)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
TBPH
Theravance Biopharma Inc
$15.29
+2.62%
HEALTHCARE · Cap: $726.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 13247% more annual revenue ($14.34B vs $107.46M). TBPH leads profitability with a 98.5% profit margin vs 31.4%. REGN trades at a lower P/E of 17.9x. TBPH earns a higher WallStSmart Score of 63/100 (C+).
REGN
Buy58
out of 100
Grade: C
TBPH
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
-402.8%
Fair Value
$3.88
Current Price
$15.29
$11.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Every $100 of equity generates 45 in profit
Keeps 99 of every $100 in revenue as profit
Strong operational efficiency at 43.6%
Revenue surging 144.7% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Moderate valuation
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : TBPH
The strongest argument for TBPH centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 98.5% and operating margin at 43.6%. Revenue growth of 144.7% demonstrates continued momentum.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : TBPH
The primary concerns for TBPH are P/E Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
REGN profiles as a value stock while TBPH is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.40 — expect wider price swings.
TBPH is growing revenue faster at 144.7% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
TBPH scores higher overall (63/100 vs 58/100), backed by strong 98.5% margins and 144.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?